Pharmafile Logo
Pharmafocus logo
Advanced Search

kite pharma

Showing 13 posts of 13 posts found.

shutterstock_3

EMA’s CHMP recommends conditional approval for Kite Pharma’s CAR T therapy for mantle cell lymphoma

October 20, 2020
Manufacturing and Production, Sales and Marketing CAR T, CAR-T, CHMP, EMA, kite pharma, lymphoma

Kite Pharma’s anti-CD19 chimeric antigen receptor (CAR) T cell therapy known as KTE-X19 has received positive recommendation from the EMA’s …

News
fdaoutsideweb

Kite secures FDA approval for second CAR T therapy Tecartus in relapsed or refractory mantle cell lymphoma

July 27, 2020
Sales and Marketing CAR T, CAR-T, FDA, Gilead, kite pharma

Kite Pharma has chalked up another regulatory success for its parent company Gilead with the news that the FDA has …

News

Gilead subsidiary Kite Pharma to open CAR-T manufacturing facility in Maryland

April 29, 2019
Manufacturing and Production, Sales and Marketing CAR-T, Gilead, Manufacturing Facility, Maryland, kite pharma

Gilead Sciences subsidiary Kite Pharma has announced plans to open a new CAR-T manufacturing facility in Frederick County, Maryland (US). …

News
scotland

Gilead’s CAR-T therapy Yescarta rejected for NHS use in Scotland

February 12, 2019
Manufacturing and Production, Sales and Marketing CAR-T, Cancer, Gilead, NHS, Scotland, Yescarta, kite pharma

It’s bad news for Scottish patients living with aggressive forms of non-Hodgkin lymphoma (NHL) as it emerges that the Scottish …

News
gilead-sciences

Gilead captures Kite in $11.9bn deal

August 29, 2017
Manufacturing and Production, Sales and Marketing Gilead, biotech, drugs, kite pharma, pharma, pharmaceutical

Gilead had long been expected to make a serious acquisition to boost flagging growth and it finally made a move …

News
kitepharma_fullcolor_rgb_1

Kite Pharma climbs on strong data showing in lymphoma trial

March 1, 2017
Research and Development kite pharma, non-Hodgkin lymphoma

Kite Pharma released the news on Rare Diseases Day promising top-line data from a Phase 1/2 trial of its treatment …

News
kitepharma_fullcolor_rgb

Kite Pharma names new senior VP of Supply Chain

December 1, 2016
Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing appointment, kite pharma

Santa-Monica-based clinical-stage biopharmaceutical firm Kite Pharma has appointed Dr Jian Irish as senior vice president of Supply Chain, who will …

Appointment
chris_nowers

Kite Pharma appoints Chris Nowers as Head of Europe

October 14, 2016
Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing Chris Nowers, London, kite pharma

Kite Pharma announced on 13 October that it had appointed Chris Nowers as its Head of Europe. Nowers will be …

Appointment
cancer-389921_960_720

Kite Pharma flying high after promising Car-T trial

September 27, 2016
Manufacturing and Production, Research and Development Cancer, Cart-T, kite pharma

Cart-T cell drugs are made by genetically altering patients’ T-cells to add a component of antibodies that make them better …

News
pauljenkinson

Kite Pharma names Paul Jenkinson CFO

May 23, 2016
Research and Development, Sales and Marketing appointment, cfo, kite pharma

Kite Pharma (Nasdaq: KITE) has appointed Paul Jenkinson its chief financial officer. Jenkinson succeeds Cynthia Butitta, who will continue in her role as …

Appointment

Kite Pharma, Roche to co-develop two new treatments for non-hodgkin lymphoma

March 18, 2016
Medical Communications, Research and Development Gentech, Roche, kite pharma, non-Hodgkin lymphoma

Kite Pharma (Nasdaq: KITE) said it will collaborate with Swiss drug major Roche (SIX: ROG) to evaluate the safety and efficacy …

News
car_t-cells

Kite Pharma says trial death was unrelated to KTE-C19

August 18, 2015
Medical Communications, Research and Development CAR-T, cinical trials, kite pharma, non-Hodgkin's lymphoma, non-Hodgkin’s lymphoma

Kite has confirmed last week’s rumours that a patient had died during its Phase I/II trial for the KTE-C19 non-Hodgkin’s …

News
Amgen image

Amgen and Novartis start cancer immunotherapy push

January 7, 2015
Research and Development, Sales and Marketing Amgen, Caribou Biosciences, Intellia Therapeutics, Novartis, kite pharma

Amgen and Novartis have launched new licensing agreements with biotech companies that they hope will lead to the development of …

News

Latest content

Ardena announces €20m expansion following first GMP approval

April 19, 2024

Roche’s Alecensa approved by FDA as lung cancer treatment

April 19, 2024

GSK shares results from phase 3 trial for gonorrhoea treatment

April 18, 2024

Eli Lilly’s tirzepatide demonstrates efficacy in reducing sleep apnoea severity

April 18, 2024

Medincell and AbbVie enter agreement for development of next-generation injectables

April 17, 2024